VectivBio

company

About

VectivBio is a biotechnology company committed to making a difference in the lives of patients suffering from serious rare diseases.

  • 51 - 100

Details

Last Funding Type
Series A
Last Funding Money Raised
$35M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2019
Number Of Employee
51 - 100
Operating Status
Active

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care.

It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$220M
VectivBio has raised a total of $220M in funding over 2 rounds. Their latest funding was raised on Mar 30, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 30, 2022 Post-IPO Debt $75M 1 Kreos Capital Detail
Oct 19, 2020 Series Unknown $110M 2 Detail
Jan 8, 2020 Series A $35M 2 Detail

Investors

Number of Lead Investors
Number of Investors
1
3
VectivBio is funded by 3 investors. Kreos Capital and Inserm Transfert Initiative are the most recent investors.
Investor Name Lead Investor Funding Round
Kreos Capital Yes Post-IPO Debt
Inserm Transfert Initiative Series Unknown
Versant Ventures Series Unknown